Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas

Acta Radiologica

Volumn 52, Issue 4, 2011, Pages 463-466

  Kao, Yung Hsiang ^a   Saad, U ^a   Tan, Andrew E H ^a   Magsombol, Butch M ^a   Padhy, Ajit Kumar ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Adults; Genital and reproductive; Metastases; Molecular imaging; PET; Uterus

Indexed keywords

ADULTS; GENITAL AND REPRODUCTIVE; METASTASES; MOLECULAR IMAGING; UTERUS;

FLUORINE; INTEGRATION; MAGNETIC RESONANCE IMAGING; PATHOLOGY; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY;

COMPUTERIZED TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LEIOMYOSARCOMA; METASTASIS; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TUMOR RECURRENCE; UTERUS CANCER;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UTERINE NEOPLASMS;

EID: 79960057607     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2011.100509     Document Type: Article

References (12)

1. Harry VN, Narayansingh GV, Parkin DE. Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls. The Obstetrician & Gynaecologist 2007;9:88-94
2. Zagouri F, Dimopoulos AM, Fotiou S, et al. Treatment of early uterine sarcomas: disentangling adjuvant modalities. World J Surg Oncol 2009;7:38
3. Kosary CL. Cancer of the corpus uteri. In: National Cancer Institute. SEER Survival Monograph. Bethesda, MD: NCI, 2008
4. NCCN clinical practice guidelines in oncology: uterine neoplasm. National Comprehensive Cancer Network V.1. 2010.
5. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32 (Pubitemid 38552885)
6. Musto A, Rampin L, Nanni C, et al. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol 2010 Jan 28 (Epub ahead of print)
7. Major FJ, Blessing JA, Silverberg SG. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702-9 (Pubitemid 23056094)
8. Dierckx RA, Van de Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 2008;35:1544-9
9. Nagamatsu A, Umesaki N, Li L, et al. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep 2010;23:1069-76
10. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 1999;12:1001-9
11. Murakami M, Tsukada H, Shida M, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006;16:854-60
12. Park JY, Kim EN, Kim DY, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol 2008;109:255-62